icon

Multicell has already experienced a nice run earlier this year, and it might be worth taking a look at the company again, whether it be for a potential short term trade or long term hold - or both, since it's always a good strategy to trade into the penny play spikes.

Shares doubled to open the tradi...

Read more

This post is intended for VFC's Stock House only. No re-publishings or re-postings are authorized. Also see News, Notes & Weekly Stock Watch at VFC's NEW Stock House.

CPST: Capstone Turbine announced last week that quarterly earnings will be released on June 14th, to be followed by a conference call ...

Read more

Take notice of the fact that Congress is gunning for Avanir Pharmaceuticals (AVNR) right now, asking the company to explain the pricing for Nuedexta, a recently-approved treatment for pseudobulbar affect (PBA).

PBA is defined as a neurological condition that leads to spontaneous episodes of laughing ...

Read more

Shares of Oncothyreon (ONTY) sprinted back up to the six dollar mark following news on Tuesday that the company had initiated the Phase II portion of the ongoing Phase I/II PX-866 trial.

The trial for Oncothyreon's anti-cancer agent was initiated late last year, and the initiation of a Phase II port...

Read more

It's been a wild ride for shares of Titan Pharmacetucials (TTNP.OB) these days, and as the expected release of Probuphine Phase III results quickly approaches, TTNP could set news highs and finally breach the long-elusive two dollar barrier.

From there shares will react to whatever is put forth by th...

Read more

This post is intended for VFC's Stock House only. No re-publishings or re-postings are authorized.

AVNR: Nuedexta, a recently-approved treatment for pseudobulbar affect (PBA) developed by Avanir, has come under the attention of Congress for the product's price, which according to Congress, looks a bi...

Read more

CVM: Cel-Sci Corp announced on Thursday that its LEAPS treatment was effective in treating the H1N1 - in mice.

The company has attempted to push LEAPS at various junctures over the past few years, most noticably during the height of of the H1N1 pandemic a couple of years ago, but the product has yet ...

Read more

TTNP: Price and Volume Spike

Posted by Posted by VFC on May 25, 2011

Titan Pharmaceuticals (TTNP.ob) traded more than 400,000 shares on Wednesday, well more than the daily normal trading average and accompanied by a five percent price spike.

Of those shares that traded in the significant late-day volume, the vast majority of them switched hands during the last half hour of the trading day.

A recent run in price brought Titan back to the $1.60 range, but the run stalled for a period of consolidation, but if Wednesday's action is any indication, then a trip towards - or past - the two dollar mark may be in the works...

Read more

Profitability may be the biggest concern for investors of Capstone Turbine (CPST), but with the orders rolling in as they have been thus far in 2011, it's hard to believe that the company won't be able to get there at some point in the near- to mid-term future.

Granted, for profitability to present i...

Read more

Shares of Apricus Biosciences (APRI) have fallen off their recent highs of over 6 dollars, although there may be a couple of short term events that could stall, or even reverse that slide.

In a Thursday morning press release, the company announced that it had received a positive response from the med...

Read more

Shares of Celldex Therapeutics (CLDX) fell sharply on Wednesday, falling by over 10% on news that the company had priced a stock offering for well below the current trading price.

Once the offering is finalized, which is expected to take place by May 23rd, according to a Wednesday press release, Cell...

Read more

Keryx Pharmaceuticals' attractive pipeline, of which the two flagship products are both well into Phase III, definitely has the company and the KERX stock on many new radars lately, and the analysts are also starting to jump on board.

This month alone, both MLV Capital and Oppenheimer have initiated coverage of the company, and slapped tags of "Buy" and "Outperform" on the stock, respectively...

Read more

Mannkind: The Wait

Posted by Posted by VFC on May 20, 2011

Just weeks ago, the future -- both short and long term -- looked bright for MannKind (MNKD), even given the FDA setback from earlier this year when Afrezza was denied for approval yet again. Optimism was there from the investor base that some of the long road to an Afrezza approval would be shortened after a recent meeting with the FDA, and at the very least, investors were looking for an update on a potential partnership deal...

Read more

GNBT: Generex will be one to keep an eye on heading into next month's shareholder vote on whether or not to approve the reverse split proposed by the company and explained in recent presentations.

If the RS does go through, investors of GNBT will be 'dividended' shares of Antigen Express, once Generex spins-off its subsidiary in an IPO...

Read more

Shares of MannKind (MNKD) were on the dive after hours on Monday following a heavily-anticipated earnings release that had many investors looking for solid notes resulting from a recent meeting with the FDA regarding the way ahead for the company's inhaled insulin product Afrezza, which was denied for approval in January...

Read more

Shares of Avanir slipped 7% Tuesday, following an earnings release that saw revenue from the recently approved Nuedexta rake in only $505,000.

Nuedexta, a treatment for pseudobulbar affect (PBA), which is a condition characterized by spontaneous fits of uncontrollable laughing and/or crying, was approved last year and has been on the market since February.

...

Read more

Cytosorbents issued their 10-Q this week, which proved to be the first in-depth follow-up to the milestone news that CytoSorb had received CE Mark approval in the European Union to treat conditions where high cytokine levels exist in the blood.

The approval came as a surprise to many, since the company had never even announced that the full 100 patients had been enrolled (only 98 were enrolled at the time of approval). The 10-Q, however, clued us in that full enrollment of 100 has been met, meaningthat results are most likely being compiled now, and the secondary endpoints that everyone is waiting on should be forthcoming...

Read more

Intended for VFC's Stock House only. No re-publishing or re-printings are authorized. Originally published at VFC's NEW Stock House.

ONTY: When Onconthyreon recently announced a stock offering of $40 million, the news stalled ONTY's run and sent shares south of the $5 mark once again, after having ju...

Read more

CVM: The ramp-up of Cel-Sci's global Phase III Multikine trial, which will measure the product's effectiveness in treating head and neck cancer, has been well documented over a number of press releases since the trial began late last year, but the recently-filed 10-Q puts another item of interest to...

Read more

Those that follow Generex Corp are well aware of the hysteria that ensued towards the latter part of last year when the company attempted to push through a reverse stock split, only to have it rejected by shareholders.

During that go-round, the company demonstrated its flair for the dramatic by announcing an eleventh hour deal to acquire Global Medical Direct (GMD), although that deal has yet to be consummated due to a lack of working capital to get the job done.

This time, the company has thrown a 'stock dividend' on the table for investors as incentive for them to vote a reverse split through this time. Shareholders would receive a "dividend" of shares from the newly-created company that results from a proposed Antigen Express IPO spin-off...

Read more

Shares of Advanced Cell Technology (ACTC) have remained relatively stable while trading for - or just below - twenty cents since rising from below a dime on news that the FDA had given an historical greent light to initiate clinical trials utilizing utilizing ACT's stem cell technology to treat...

Read more

SIGA: It's been a roller coaster ride for Siga Technlogies during the lead-up to landing a BARDA contract to supply the US with a reserve of a smallpox vaccine to combat a potential bioterror attack.

It now looks like the final tally is in, and Siga has been awarded the contract - again.

On Friday, Si...

Read more

Couldn't help but comment on this one.

In TheStreet.com's weekly 'Biotech Stock Mailbag' - for which a more fitting title might be 'Feuerstein's Ode To Himself' - the biotech blogger made a couple of comments that were too comical to ignore.

...

Read more

Briefs: CELH, TLON, CVM

Posted by Posted by VFC on May 03, 2011

CELH: The most recent relevant announcement from Celsius was the positive preliminary look at the first quarter numbers which finally show a positive trend in recent sales, although the number was still down from the first quarter of the previous year.

The company has been mentioned as a competitor, ...

Read more